In Plain English:
AICAR (acadesine) is not a peptide — it is a naturally occurring nucleoside analog and intermediate in purine biosynthesis. Once injected, cells convert it into ZMP, a molecule that mimics AMP and fools the body's master energy sensor (AMPK) into thinking energy is low. This triggers the same downstream cascade as endurance exercise: fat burning, glucose uptake, mitochondrial growth, and inflammatory suppression. In a landmark 2008 mouse study, AICAR alone — no exercise — boosted treadmill endurance by 44%. It has been in human Phase III clinical trials for cardiac surgery and has full WADA-prohibited status, which tells you it works well enough to worry competitive sport.
Research Maturity
Phase III (~2,100 PubMed papers on AICAR/AMPK; >1,700 covered in a 2021 systematic review+ Studies)
Focus
Cardiometabolic Health
Endurance & Performance
Metabolic Signaling
Origin
AICAR (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, CAS 2627-69-2) is an endogenous intermediate of the de novo purine synthesis pathway, first isolated from Bacillus subtilis. It gained pharmacological interest in the 1980s as a cardioprotective agent under the name acadesine and was licensed to Schering-Plough for Phase III cardiac surgery trials in 2007. WADA banned it in competition and out of competition from January 2009 under the Hormone and Metabolic Modulators category after lab evidence confirmed performance-enhancing endurance effects in animal models.
Mechanism
AICAR enters cells via the equilibrative nucleoside transporter ENT1. Inside, adenosine kinase phosphorylates it to ZMP (AICA ribonucleotide monophosphate) — an AMP analog. ZMP accumulates intracellularly (reaching millimolar concentrations) and binds the γ-subunit of the AMPK heterotrimer, promoting allosteric activation and enhancing phosphorylation at Thr172 on the α-subunit by upstream kinases LKB1 and CaMKKβ. AMPK activation triggers: inhibition of ACC (acetyl-CoA carboxylase) → fatty acid oxidation; GLUT4 translocation → insulin-independent glucose uptake; PGC-1α induction → mitochondrial biogenesis; mTORC1 suppression → reduced anabolic signalling. CRITICAL CAVEAT: a 2021 systematic review of >1,700 PubMed studies (PMC8147799) established that many effects attributed to AMPK activation are in fact AMPK-independent, driven by ZMP's disruption of purine/pyrimidine metabolism and by extracellular adenosine accumulation. ZMP is also 40–50x less potent than AMP at AMPK activation, explaining why millimolar concentrations are required.
Outcome
Animal models: 44% increase in treadmill running endurance without training (2008 Cell study, Narkar et al.); improved insulin sensitivity; fat mass reduction; neuroprotection in diabetic polyneuropathy models; anti-tumour activity in lymphoma and leukemia cells. Human cardiac surgery (5-trial meta-analysis, 4,043 CABG patients): 27% reduction in perioperative MI, 50% reduction in early cardiac death through day 4, 26% reduction in combined MI/stroke/cardiac death (Multicenter Study of Perioperative Ischemia, JAMA 1997). The subsequent RED-CABG Phase III trial (3,080 patients, 2012) showed no benefit in a higher-risk population, with primary endpoint rates of 5.0% placebo vs 5.1% acadesine, and was stopped early by futility analysis. Cancer Phase I/II (CLL, 2013): MTD 210 mg/kg IV, acceptable safety; halted in MDS/AML (2019) due to serious renal toxicity at high doses. WADA-banned since 2009.
